Business
BioInvent International AB: Interim Report January - March 2026
LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV) "During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), ...
About this update from Bioinvent International Ab
[{"type":"text","content":"LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV)","length":80,"tagName":"p"},{"type":"text","content":""During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), with the goal of advancing these innovative immune-modulatory antibodies for patients who urgently need better treatment options."- Martin Welschof, CEO of BioInvent.","length":357,"tagName":"p"},{"type":"text","content":"EVENTS IN THE FIRST QUARTER","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"(R) Promising data in ongoing Phase 2a study for BI-1808 with KEYTRUDA® (pembrolizumab) for the treatment of recurrent ovarian cancer","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Updated clinical data sets solidify potential for both BI-1808 and pembrolizumab combination in ovarian cancer and BI-1206 triplet for the treatment of NHL, see pages 6 and 7 in the year-end report","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"Nomination of two new board members ahead of 2026 Annual General Meeting; Kate Hermans and Scott Zinober","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 3 milestone achieved for HMI-115 in endometriosis","length":55,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":489,"olType":false},{"type":"text","content":"EVENTS AFTER THE END OF THE PERIOD","length":34,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"BI-1808 plus KEYTRUDA® data in recurrent ovarian cancer to be presented at the 2026 ASCO Annual Meeting","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":103,"olType":false},{"type":"text","content":"(R)= Regulatory event","length":21,"tagName":"p"},{"type":"text","content":"FINANCIAL INFORMATIONFirst quarter 2026• Net sales SEK 13.4 (22.1) million.• Profit/loss after tax SEK -119.2 (-116.6) million.• Profit/loss after tax per share before and after dilution SEK -1.81 (-1.77).• Cash flow from operating activities SEK -132.8 (-120.0) million.• Liquid funds, current and long-term investments as of March 31, 2026: SEK 456.5 (742.2) million.","length":375,"tagName":"p"},{"type":"text","content":"The complete interim report is available for downlo...